Mycrodose Therapeutics is a pharmaceutical company specialized in the development of advanced drug delivery systems utilizing psychedelic APIs to treat mental health and cognitive degenerative diseases. Their primary dosing technology utilizes a proprietary sustained microdosing delivery method.
Their advanced drug delivery technologies are split into four distinct models: Transdermal, Oral, Implants, and Capsules.
Transdermal technology delivers a sustained and controlled dose of medicine directly into the bloodstream, bypassing the liver, to reduce the potential of harmful toxicity, psychosis, and the common issues associated with standard macro dosing products.
Sustained-release lozenge technology is utilized to deliver a sustained and controlled dose of medicine via the oral cavity into the body. The delivery duration can be custom-tailored to last from 30 minutes up to more than 2 hours.
Sustained-release capsules deliver a controlled dose of medicine by encapsulating the psychedelic API so that medicine is slowly released over many hours into the body, reducing the common issues associated with standard macro dosing.
Biodegradable implants will be used to deliver medicine for longterm addiction and Alzheimer’s treatments.